Literature DB >> 16481920

Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-delivery applications.

Alexander L Klibanov1.   

Abstract

The use of microbubble contrast agents for general tissue delineation and perfusion enjoys steady interest in ultrasound imaging. Microbubbles as contrast materials require a small dosage and show excellent detection sensitivity. Targeting ligands on the surface of microbubbles permit the selective accumulation of these particles in the areas of interest, which show an up-regulated level of receptor molecules on vascular endothelium. Selective contrast imaging of inflammation, ischemia-reperfusion injury, angiogenesis, and thrombosis has been achieved in animal models. Ultrasound-assisted drug delivery and activation, performed by combining microbubble agent containing drug substances or coadministered with pharmaceutical agents (including plasmid DNA for transfection), has been achieved in multiple model systems in vitro and in vivo. Ultrasound and microbubbles-based targeted acceleration of the thrombolytic enzyme action already have reached clinical trials. Overall, microbubble targeting and ultrasound-assisted microbubble-based drug-delivery systems will offer a step toward the application of targeted personalized diagnostics and therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16481920     DOI: 10.1097/01.rli.0000199292.88189.0f

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  106 in total

Review 1.  Gene therapy in the cornea: 2005--present.

Authors:  Rajiv R Mohan; Jonathan C K Tovey; Ajay Sharma; Ashish Tandon
Journal:  Prog Retin Eye Res       Date:  2011-09-28       Impact factor: 21.198

2.  Model for bubble pulsation in liquid between parallel viscoelastic layers.

Authors:  Todd A Hay; Yurii A Ilinskii; Evgenia A Zabolotskaya; Mark F Hamilton
Journal:  J Acoust Soc Am       Date:  2012-07       Impact factor: 1.840

3.  scVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis.

Authors:  Christopher R Anderson; Joshua J Rychak; Marina Backer; Joseph Backer; Klaus Ley; Alexander L Klibanov
Journal:  Invest Radiol       Date:  2010-10       Impact factor: 6.016

4.  Molecular ultrasound imaging and its potential for paediatric radiology.

Authors:  Isabel Kiessling; Jessica Bzyl; Fabian Kiessling
Journal:  Pediatr Radiol       Date:  2010-08-03

5.  Thermal ablation for unresectable liver tumours, time to move forward?

Authors:  Gianpiero Gravante
Journal:  World J Gastrointest Surg       Date:  2010-01-27

6.  Optimization of low-frequency low-intensity ultrasound-mediated microvessel disruption on prostate cancer xenografts in nude mice using an orthogonal experimental design.

Authors:  Y U Yang; Wenkun Bai; Yini Chen; Yanduan Lin; Bing Hu
Journal:  Oncol Lett       Date:  2015-09-17       Impact factor: 2.967

7.  Design of ultrasonically-activatable nanoparticles using low boiling point perfluorocarbons.

Authors:  Paul S Sheeran; Samantha H Luois; Lee B Mullin; Terry O Matsunaga; Paul A Dayton
Journal:  Biomaterials       Date:  2012-01-29       Impact factor: 12.479

8.  Acoustically-active microbubbles conjugated to liposomes: characterization of a proposed drug delivery vehicle.

Authors:  Azadeh Kheirolomoom; Paul A Dayton; Aaron F H Lum; Erika Little; Eric E Paoli; Hairong Zheng; Katherine W Ferrara
Journal:  J Control Release       Date:  2006-12-23       Impact factor: 9.776

9.  An iterative fullwave simulation approach to multiple scattering in media with randomly distributed microbubbles.

Authors:  Aditya Joshi; Brooks D Lindsey; Paul A Dayton; Gianmarco Pinton; Marie Muller
Journal:  Phys Med Biol       Date:  2017-03-07       Impact factor: 3.609

10.  Toward ultrasound molecular imaging with phase-change contrast agents: an in vitro proof of principle.

Authors:  Paul S Sheeran; Jason E Streeter; Lee B Mullin; Terry O Matsunaga; Paul A Dayton
Journal:  Ultrasound Med Biol       Date:  2013-02-27       Impact factor: 2.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.